ReviewNeuroImage. Clinical2018
Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.
Review in NeuroImage. Clinical, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.Neurology · 2022Pooled it
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Magnetic resonance imaging in multiple sclerosis animal models: A systematic review, meta-analysis, and white paper.NeuroImage. Clinical · 2020Pooled it
- Repeatability and reproducibility of brain age estimates in multiple sclerosis for three publicly available models.Neuroimage. Reports · 2025Article
- Radiological Reporting of Brain Atrophy in MRI: Real-Life Comparison Between Narrative Reports, Semiquantitative Scales and Automated Software-Based Volumetry.Diagnostics (Basel, Switzerland) · 2025Article
- Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.Annals of clinical and translational neurology · 2025Article
- Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.Journal of neurology · 2024Article
- Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients.Brain and behavior · 2023Article
- Reliability of brain atrophy measurements in multiple sclerosis using MRI: an assessment of six freely available software packages for cross-sectional analyses.Neuroradiology · 2023Article
- Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.Journal of neurology · 2023Article
- The effect of lesion filling on brain network analysis in multiple sclerosis using structural magnetic resonance imaging.Insights into imaging · 2022Article
- Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- Perivascular space is associated with brain atrophy in patients with multiple sclerosis.Quantitative imaging in medicine and surgery · 2022Article
- Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.Neurology · 2021Review
- Generating Longitudinal Atrophy Evaluation Datasets on Brain Magnetic Resonance Images Using Convolutional Neural Networks and Segmentation Priors.Neuroinformatics · 2021Article
- Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal.Nature reviews. Neurology · 2021Review
- MRI Prognostic Factors in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Antibody Disease.Frontiers in neurology · 2021Review
- Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort.Journal of neurology · 2020Article
- Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis.JCI insight · 2020Article
- Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study.Contemporary clinical trials communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.